Medical

Data presented at the 2011 American Thoracic Society (ATS) meeting by Novartis regarding combined indacaterol and tiotropium therapy for COPD demonstrate that the LABA/LAMA combination produced greater improvement in lung function than tiotropium alone. Novartis’s… Read more . . .

A report by the American Lung Association in California claims that a “car of the future” scenario in which zero emission vehicles replace a large percentage of the existing fleet of cars in the state… Read more . . .

An article in the May 5 issue of the New England Journal of Medicine finds leukotriene-receptor antagonists (LTRAs) such as montelukast (Singulair) as effective as ICS as a first-line treatment for asthma and as effective… Read more . . .

A Phase 2 clinical trial of its bepotastine besilate nasal spray for the treatment of seasonal allergic rhinitis has demonstrated significantly significant improvement in total nasal symptoms compared to placebo, announced ISTA Pharmaceuticals. The study… Read more . . .

NVA237, a once daily, long acting muscarinic agent (LAMA) DPI for the treatment of COPD, met its primary endpoint of improved bronchodilation compared to placebo after 12 weeks. The glycopyrronium bromide dry powder formulation was… Read more . . .

Dennis Metzger of Albany Medical College (Albany, New York) has presented research at the Society for General Microbiology Spring Conference demonstrating the effectiveness of using interleukin-12 (IL-12) in combination with intranasally-delivered vaccines to boost immune… Read more . . .

According to Meda Pharmaceuticals, a Phase 3 trial has shown that its Dymista nasal spray, a combination formulation of azelastine hydrochloride and fluticasone propionate, produced a 40% greater improvement in nasal symptoms than fluticasone alone.… Read more . . .